Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$221K Hold
610
0.11% 26
2026
Q1
$215K Sell
610
-50
-8% -$17.8K 0.12% 25
2025
Q4
$216K Buy
+660
New +$209K 0.12% 26
2025
Q2
Sell
-715
Closed -$223K 27
2025
Q1
$223K Sell
715
-339
-32% -$100K 0.14% 24
2024
Q4
$275K Sell
1,054
-20
-2% -$5.93K 0.17% 24
2024
Q3
$346K Buy
1,074
+5
+0.5% +$1.64K 0.17% 24
2024
Q2
$334K Buy
1,069
+47
+5% +$13.8K 0.17% 25
2024
Q1
$291K Hold
1,022
0.16% 26
2023
Q4
$294K Hold
1,022
0.17% 23
2023
Q3
$275K Buy
+1,022
New +$255K 0.17% 25
2023
Q2
Sell
-1,042
Closed -$252K 27
2023
Q1
$252K Hold
1,042
0.16% 25
2022
Q4
$274K Sell
1,042
-61
-6% -$16.4K 0.19% 24
2022
Q3
$249K Hold
1,103
0.18% 26
2022
Q2
$268K Hold
1,103
0.19% 20
2022
Q1
$267K Sell
1,103
-20
-2% -$4.59K 0.16% 23
2021
Q4
$253K Sell
1,123
-196
-15% -$41.4K 0.15% 25
2021
Q3
$280K Buy
1,319
+20
+2% +$4.6K 0.18% 21
2021
Q2
$317K Hold
1,299
0.21% 19
2021
Q1
$336K Buy
1,299
+344
+36% +$82.1K 0.24% 19
2020
Q4
$220K Buy
+955
New +$220K 0.19% 22

Other funds holding AMGN

BCK Partners's AMGN Position: Q2 2026 in Review

BCK Partners held its Amgen (AMGN) position steady in Q2 2026 at 610 shares worth $221K. The position accounts for 0.11% of the portfolio, ranked #26.

BCK Partners first reported a position in AMGN in Q4 2020 and has held it in 20 quarters since. The position peaked at $346K in Q3 2024. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • BCK Partners held 610 shares of Amgen worth $221K as of Q2 2026.
  • BCK Partners left its Amgen share count unchanged in Q2 2026.
  • Amgen made up 0.11% of BCK Partners's portfolio in Q2 2026, its #26 holding.
  • BCK Partners first reported a position in Amgen in Q4 2020 and has held it in 20 quarters since.
  • BCK Partners's Amgen position peaked at $346K in Q3 2024.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on BCK Partners's 13F filing for Q2 2026, filed 20 Jul 2026.